Juliet Tammenoms Bakker

Myopia is the most common eye disease in children and has experienced a dramatic increase in prevalence over the last 30 years. Once considered a benign refractive condition, even at low levels, myopia is now associated with many serious ophthalmic co- morbidities. The greater myopia severity, the higher the risk of these ophthalmic co-morbidities later in life. Sydnexis was founded with the goal of developing a proprietary, stable, low-dose atropine eyedrop to treat myopia progression in children and minimize the risk of ocular co-morbidities. At Sydnexis, we have focused on developing a best-in-class low-dose atropine formulation to address the juvenile-onset myopia pandemic.

Ceribell is a fast growing venture-backed medical device start-up company founded by two faculty members at Stanford University. Our primary mission is to improve neurological care for emergency and ICU patients. Ceribell is focused on making EEG widely accessible, more efficient, and more cost-effective to improve the diagnosis and treatment of patients at risk for seizures. The System can be set up by any healthcare provider within minutes. Now with Clarity, Ceribell offers 24/7 continuous bedside EEG monitoring and alert.

You never think about your hearing. At least, not until you lose it. Then it’s the only thing on your mind. Our ability to hear connects us to the world, and most importantly, to the people we love. Over the last decade, the assault on our ears has been relentless through the non-stop streaming, video gaming, music festivals and video calls. And it’s not who you think that’s at risk—the World Health Organization predicts over 1 billion young adults 35 and under are in danger of hearing loss today. Because anyone can experience hearing loss, regardless of age. At Eargo, it’s our mission to change the way the world perceives hearing loss by making every aspect of your hearing journey as invisible as possible, so you never have to think about it. From the design of our devices, intuitive mobile app, extensive personalization options, rechargeable battery, lifetime customer support, Eargo is meant to amplify your life without compromising your lifestyle. Because this is the future of micro-hearing technology. Though the world is getting louder, hearing loss is a silent pandemic nobody is talking about. And Eargo was built to start a conversation about it, because life deserves to be heard. Eargo is designed for mild to moderate hearing loss. Will not restore normal hearing. Full benefit best obtained with frequent use. Visit Eargo.com/guides for more information and labeling.

Endogenex is a clinical stage company focused on improving outcomes and quality of life for patients living with Type 2 Diabetes (T2D). Endogenex has developed a novel therapy that utilizes pulsed electric fields to promote regeneration of the duodenal mucosa for improvement in glycemic control in patients with T2D.

Axonics® is dedicated to improving the quality of life of people suffering from bladder and bowel dysfunction, conditions that impact the lives of tens of millions of adults globally. The Company’s products include the Axonics Sacral Neuromodulation System designed to treat overactive bladder and fecal incontinence and the Bulkamid® hydrogel designed to treat women with stress urinary incontinence. For more information, visit www.axonics.com and www.bulkamid.com.   Axonics, Inc. (Nasdaq: AXNX) is headquartered in Irvine, California.

Nalu Medical, Inc. is a privately held commercial medical device company based in Carlsbad, California. The Nalu neurostimulation system is a battery-free, micro-implantable pulse generator (iPG) currently cleared by the FDA for both Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS) for mitigating chronic pain. The system is highly capable and easily upgradeable, providing a menu of therapy options.

Venus: A Global Leader In The Medical Aesthetics Industry We use cutting-edge technology to develop safe, non-invasive devices that address todays most in-demand aesthetic needs. As a leading medical aesthetic device company, we are currently present in over 60 countries and 29 direct markets with more than 10 million Venus treatments performed worldwide annually. Staying connected to our customers enables us to be focused on their needs and expectations and always provide them with the highest level of care – this is the essence of Aesthetic intelligence. Our latest innovations like Venus Bliss MAX™ the 3-in1-body shaping solution, ARTAS iXi® the A.I. hair restoration robot, NeoGraft®, Venus Legacy,™ Venus Velocity,™ Venus Viva™ MD—are setting higher industry standards and improving the quality of life for hundreds of thousands of patients worldwide. Looking to try a treatment? Find a certified provider near you: ‪http://www.venustreatments.com Are you a physician? Find out more: www.venus.ai

Myopia is the most common eye disease in children and has experienced a dramatic increase in prevalence over the last 30 years. Once considered a benign refractive condition, even at low levels, myopia is now associated with many serious ophthalmic co- morbidities. The greater myopia severity, the higher the risk of these ophthalmic co-morbidities later in life. Sydnexis was founded with the goal of developing a proprietary, stable, low-dose atropine eyedrop to treat myopia progression in children and minimize the risk of ocular co-morbidities. At Sydnexis, we have focused on developing a best-in-class low-dose atropine formulation to address the juvenile-onset myopia pandemic.

Ceribell is a fast growing venture-backed medical device start-up company founded by two faculty members at Stanford University. Our primary mission is to improve neurological care for emergency and ICU patients. Ceribell is focused on making EEG widely accessible, more efficient, and more cost-effective to improve the diagnosis and treatment of patients at risk for seizures. The System can be set up by any healthcare provider within minutes. Now with Clarity, Ceribell offers 24/7 continuous bedside EEG monitoring and alert.

You never think about your hearing. At least, not until you lose it. Then it’s the only thing on your mind. Our ability to hear connects us to the world, and most importantly, to the people we love. Over the last decade, the assault on our ears has been relentless through the non-stop streaming, video gaming, music festivals and video calls. And it’s not who you think that’s at risk—the World Health Organization predicts over 1 billion young adults 35 and under are in danger of hearing loss today. Because anyone can experience hearing loss, regardless of age. At Eargo, it’s our mission to change the way the world perceives hearing loss by making every aspect of your hearing journey as invisible as possible, so you never have to think about it. From the design of our devices, intuitive mobile app, extensive personalization options, rechargeable battery, lifetime customer support, Eargo is meant to amplify your life without compromising your lifestyle. Because this is the future of micro-hearing technology. Though the world is getting louder, hearing loss is a silent pandemic nobody is talking about. And Eargo was built to start a conversation about it, because life deserves to be heard. Eargo is designed for mild to moderate hearing loss. Will not restore normal hearing. Full benefit best obtained with frequent use. Visit Eargo.com/guides for more information and labeling.

Endogenex is a clinical stage company focused on improving outcomes and quality of life for patients living with Type 2 Diabetes (T2D). Endogenex has developed a novel therapy that utilizes pulsed electric fields to promote regeneration of the duodenal mucosa for improvement in glycemic control in patients with T2D.

Axonics® is dedicated to improving the quality of life of people suffering from bladder and bowel dysfunction, conditions that impact the lives of tens of millions of adults globally. The Company’s products include the Axonics Sacral Neuromodulation System designed to treat overactive bladder and fecal incontinence and the Bulkamid® hydrogel designed to treat women with stress urinary incontinence. For more information, visit www.axonics.com and www.bulkamid.com.   Axonics, Inc. (Nasdaq: AXNX) is headquartered in Irvine, California.